GGrantIndex
Sort

326,823 grants matching clinical trial

Action for Health in Diabetes (Look AHEAD)

$1,595,718
David M Nathan · Massachusetts General Hospital · U01 · FY2012 · DK

ZW800-1: The 1st Zwitterionic NIR Fluorophore for Cancer Imaging & Ureter Mapping

$1,595,693
John V Frangioni · Curadel, Llc · R44 · FY2021 · CA

ZW800-1: The 1st Zwitterionic NIR Fluorophore for Cancer Imaging & Ureter Mapping

$1,595,693
John V Frangioni · Curadel, Llc · R44 · FY2020 · CA

Alliance for Clinical Trials in Oncology Operations Center

$1,595,651
Monica M Bertagnolli · Brigham And Women'S Hospital · U10 · FY2016 · CA

Core--Vector

$1,595,516
Jaap Goudsmit · Beth Israel Deaconess Medical Center · U19 · FY2007 · AI

Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease

$1,595,511
Li-Huei Tsai · Massachusetts Institute Of Technology · U01 · FY2021 · AG

MSKCC -Cornell Center for Translation of Cancer Nanomedicines.

$1,595,317
Michelle S Bradbury · Sloan-Kettering Inst Can Research · U54 · FY2018 · CA

Achieving Safe, Comprehensive, Digitally-Enabled Cancer Pain managemeNT” (ASCENT) Clinical Trial

$1,595,294
Andrea Lynne Cheville · Mayo Clinic Rochester · R33 · FY2025 · CA

COLORADO ADULT AIDS CLINICAL TRIALS UNIT

$1,595,271
Thomas B. Campbell · University Of Colorado Denver · U01 · FY2006 · AI

A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease

$1,595,216
Richard C. Mohs · Agenebio, Inc. · R01 · FY2022 · AG

A Pragmatic Clinical Trial of MyPEEPS Mobile to Improve HIV prevention Behaviors in Diverse Adolescent MSM

$1,595,193
Rebecca Schnall · Columbia University Health Sciences · U01 · FY2016 · MD

Emergency Department Safety Assessment and Follow-Up Evaluation (EDSAFE) Trial

$1,594,969
Edwin D Boudreaux · Univ Of Massachusetts Med Sch Worcester · U01 · FY2013 · MH

Novel Small Molecule Inhibitors of Botulinum Neurotoxin A

$1,594,896
Terry L Bowlin · Microbiotix, Inc · U01 · FY2007 · AI

Trial to Assess Chelation Therapy 2 (TACT2) DCC

$1,594,889
Kevin J Anstrom · Duke University · UH3 · FY2019 · AT

Modification of hyperthermia response

$1,594,884
Thomas Jefferson University · P01 · FY2005 · CA

Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb

$1,594,873
Misty Ward Stevens · Intervexion Therapeutics, Llc · U01 · FY2015 · DA

ICH Removal: Minimally Invasive Surgery + rt-PA

$1,594,839
Daniel F Hanley · Johns Hopkins University · R01 · FY2010 · NS

Coalition for harm reduction and prevention (CHRP): Developing and testing a novel Hub and Spoke Model to implement prevention and harm reduction in rural clinics

$1,594,805
Lewei Allison Lin · University Of Michigan At Ann Arbor · R61 · FY2024 · DA

Implementation science to scale and sustain tobacco treatment leveraging point of care paradigm and health information technology

$1,594,797
Li-Shiun Chen · Washington University · UG3 · FY2025 · CA

Anatomic Pathology Residency Program

$1,594,760
John Oberholtzer · Division Of Basic Sciences - Nci · ZIE · FY2011 · CA

Achieving Equity through SocioCulturally-informed, Digitally-Enabled Cancer Pain managemeNT” (ASCENT) Clinical Trial

$1,594,666
Andrea Lynne Cheville · Mayo Clinic Rochester · R33 · FY2024 · CA

Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for AD

$1,594,649
William C Raschke · Virogenics, Inc. · U01 · FY2024 · AG

PROSTATE, LUNG, COLORECTAL AND OVARIAN CANCER

$1,594,634
Henry Ford Health System · N01 · FY2000 · CN

Preclinical Development of JNK3 Inhibitors to Treat Parkinson's Disease

$1,594,607
Philip Lograsso · Scripps Research Institute, The · U01 · FY2012 · NS

Preclinial Development of JNK3 Inhibitors to Treat Parkinson's Disease

$1,594,607
Philip Lograsso · Scripps Research Institute, The · U01 · FY2012 · NS